Valneva SE Sponsored ADR (NASDAQ:VALN) Given Consensus Rating of “Hold” by Analysts

Valneva SE Sponsored ADR (NASDAQ:VALN) has received a consensus recommendation of “Hold” from the five brokerages that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $11.9750.

Several research analysts have issued reports on the stock. The Goldman Sachs Group cut shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 target price for the company. in a report on Wednesday, April 22nd. Guggenheim set a $11.00 price target on shares of Valneva in a research report on Thursday, April 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Valneva in a report on Thursday, June 18th. Finally, Wall Street Zen raised Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of VALN. VSM Wealth Advisory LLC lifted its holdings in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after purchasing an additional 5,000 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Valneva in the 4th quarter worth about $44,000. JPMorgan Chase & Co. bought a new position in Valneva during the 3rd quarter valued at about $124,000. XTX Topco Ltd bought a new position in Valneva during the 4th quarter valued at about $94,000. Finally, Marex Group plc purchased a new stake in shares of Valneva during the 2nd quarter valued at about $64,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Price Performance

Shares of NASDAQ:VALN opened at $5.22 on Monday. Valneva has a 1-year low of $5.04 and a 1-year high of $12.25. The company has a debt-to-equity ratio of 2.14, a current ratio of 2.14 and a quick ratio of 1.60. The business has a fifty day moving average price of $5.57 and a 200-day moving average price of $7.75. The company has a market capitalization of $495.33 million, a PE ratio of -2.79 and a beta of 1.77.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share (EPS) for the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%.The firm had revenue of $35.77 million during the quarter. As a group, equities analysts expect that Valneva will post -1 EPS for the current fiscal year.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.